NICE
NICE says no to GSK breast cancer drug
June 10, 2010Sales and Marketing NICE, Tyverb
NICE has issued final draft guidance restricting use of GlaxoSmithKline’s breast cancer drug Tyverb to clinical trials, citing high cost …
NICE rejects Xolair for children
June 3, 2010Sales and Marketing NICE, Xolair, asthma
The drug was first approved in Europe in November 2005 for patients aged 12 or older, and gained NICE approval …
Thalidomide recommended ahead of Velcade
June 2, 2010Medical Communications NICE, myeloma
Celgene’s Thalidomide has been recommended by NICE as a treatment for multiple myeloma, and is favoured ahead of Janssen-Cilag’s Velcade. …
NICE rejects Bayer’s liver cancer drug
May 26, 2010Sales and Marketing NICE, Nexavar, patient access scheme
Bayer’s liver cancer drug Nexavar has been rejected by NICE after it deemed the drug too costly for a marginal …
NICE responds to Daily Mail cancer drug claims
April 12, 2010Sales and Marketing NICE, Sutent, election, off label
NICE has responded to a Daily Mail article on access to cancer drugs, in order to clear up claims of …
Conservative claims on cancer drugs disputed
April 6, 2010Sales and Marketing NHS, NICE, election
A think tank has disputed Conservative claims that funds can be diverted to pay for greater access to new cancer …
NICE changes its mind on Multaq
March 30, 2010Sales and Marketing Multaq, NICE, Sanofi-Aventis
NICE has given preliminary approval of Sanofi-Aventis’ Multaq for the management of patients with atrial fibrillation. The decision reverses an …
NICE seeks compromise over Glivec approval
March 24, 2010Sales and Marketing Glivec, NICE, Novartis
NICE says it is unlikely to approve the use of Glivec against gastrointestinal stromal tumours (GISTs) after surgery, but is …
Conventional hypertension prescribing ‘should be reconsidered’
March 16, 2010NICE, hypertension
New findings throwing doubt on conventional wisdom about high blood pressure may have implications for NICE’s advice on hypertension. Published …
Vidaza too costly for NICE
March 8, 2010Sales and Marketing Celgene, NICE, Vidaza
NICE has rejected Celgene’s Vidaza for use on the NHS to treat the rare bone marrow disease myelodysplastic syndrome. The …
NICE approves Yondelis
February 24, 2010Sales and Marketing NICE, PharmaMar, Yondelis
Cancer drug Yondelis has been approved by NICE for use on the NHS, but only after the manufacturer offered to …
Novo to challenge NICE Victoza guidance
February 15, 2010Sales and Marketing NICE, Novo Nordisk, Victoza
NICE has given a partial green light to Novo Nordisk’s type II diabetes treatment Victoza, backing its use as part …
NICE warns industry on cost-effectiveness
February 9, 2010Sales and Marketing BMS, Janssen, NICE, Novartis, hta
NICE has turned down three drugs on cost grounds and has urged the pharma industry to do more to help …
Servier fails to overturn NICE osteoporotic guidance
February 2, 2010Sales and Marketing NICE, Servier, osteoporosis
Servier’s challenge to NICE guidance on preventing osteoporotic fractures has proved unsuccessful, with the watchdog’s original decision still standing. This …
Patient access scheme secures NICE approval for Cimzia
January 22, 2010Sales and Marketing Cimzia, NICE, UCB, rheumatoid arthritis
UCB Pharma’s Cimzia has been recommended by NICE to treat rheumatoid arthritis – but only if a patient access scheme …
